Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha(1)-adrenoceptor antagonist.
OBJECTIVE
To evaluate the incidence of Intraoperative Floppy Iris syndrome (IFIS) in relation to the usage of alpha(1)-adrenoceptor antagonists.


METHODS
Prospective, interventional case series.


METHODS
In 2,643 consecutive eyes of 1,968 patients undergoing cataract surgery, occurrence of IFIS and use of alpha(1) antagonists were recorded.


RESULTS
IFIS was observed in 29 eyes (1.1%) of 25 male patients, all of whom were receiving alpha(1) antagonists. In those receiving systemic tamsulosin, alpha(1A) selective antagonist, IFIS developed in 25 (43.1%) of 58 eyes. In those receiving systemic naftopidil, alpha(1A) and alpha(1D) antagonists, IFIS was found in 4 (19.0%) of 21 eyes. There was no case of IFIS in patients who received other systemic alpha(1) antagonists and in eyes treated with bunazosin eyedrops, a nonselective alpha(1) antagonist.


CONCLUSIONS
IFIS occurred in 1.1% of cases treated with systemic alpha(1A)-adrenoceptor antagonists for benign prostatic hypertrophy. Topical nonselective alpha(1) antagonist did not induce IFIS.
Oshika
Tetsuro
T
Department of Ophthalmology, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennidai, Tsukuba, Ibaraki 305-8575, Japan. toshika@md.tsukuba.ac.jp
Ohashi
Yuichi
Y
Inamura
Mikio
M
Ohki
Kohtaro
K
Okamoto
Shigeki
S
Koyama
Tetsuro
T
Sakabe
Isao
I
Takahashi
Kazuhiro
K
Fujita
Yoshifumi
Y
Miyoshi
Teruyuki
T
Yasuma
Tetsushi
T
D000287:Administration, Topical; D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects*; D002387:Cataract Extraction; D005260:Female; D006801:Humans; D015994:Incidence; D007431:Intraoperative Complications; D007499:Iris Diseases / Q000139:chemically induced*; D008297:Male; D009281:Naphthalenes / Q000009:adverse effects; D010879:Piperazines / Q000009:adverse effects; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000188:drug therapy; D011680:Pupil / Q000187:drug effects*; D011799:Quinazolines / Q000009:adverse effects; D013449:Sulfonamides / Q000009:adverse effects; D013577:Syndrome; D000077409:Tamsulosin
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D009281:Naphthalenes; D010879:Piperazines; D011799:Quinazolines; D013449:Sulfonamides; C018176:bunazosin; D000077409:Tamsulosin; C064357:naftopidil